8.30 Check-In & Morning Coffee
9:20 am Chair’s Opening Remarks
Achieving an Asian Decentralized Manufacturing Platform to Support Development of mRNA Vaccines for Emerging Health Threats & Future Pandemics
9:30 am Establishing a Two-Track Strategy & Platform Technology Required for Next Pandemic Preparedness
Synopsis
- Advancing decentralized manufacturing
- Developing extra long-term storage
- Combating pandemic preparedness
10:00 am Building a Decentralized & Accelerated mRNA Vaccine Production System (DeCAFx) for Pandemic Preparedness
Synopsis
- DeCAFx, led by IVI, is a decentralized, modular mRNA manufacturing platform for rapid, regional pandemic response
- Collaborating globally on mRNA R&D, including vaccines for Lassa and Rift Valley fevers, saRNA, and novel delivery methods
- Aligning with CEPI’s 100 Days Mission, DeCAFx aims to enable vaccine rollout within weeks of pathogen detection
10:30 am Innovative Cap Analog Design Advancing mRNA-Based Therapeutics
Synopsis
- Novel cap analogs are synthesized through rational design to minimize IFIT1 interaction, named HiXCaps
- HiXCaps capped mRNA demonstrates elevated translation efficiency under conditions where interferon responses are activated
- Presenting case studies on mRNA vaccines utilizing HiXCaps
11.00 Morning Break & Networking
11:50 am Synthetic DNA: The New Standard in Scalable GMP-Grade Manufacture for mRNA Therapeutics
Synopsis
- Exploring opDNA®, an application-specific IVT template open at the 3’ end, facilitating direct use in the IVT reaction without enzymatic linearization. As a linear template without bacterial backbone sequences, equivalent mRNA yields are achieved with less DNA mass
- Homologous recombination of polyA tails in bacterial hosts is a major limitation of plasmid DNA. 4basebio’s enzymatic platform can handle long polyA tails (>180 bp) encoded directly into the template, while our novel polyA analytics ensure homogeneity in every construct
- Clinically validated and regulatory-ready, opDNA® supports efficient, flexible, and compliant manufacturing.Â
- This approach can support clinical programs at every scale, from large-scale production to small-batch and scale-out demands of personalized immunotherapies
12:00 pm Thermostable mRNA Vaccines using Hybrid Polymer-Lipid Nanoparticles
Synopsis
- Presenting a polymer-based nanoparticles for vaccines and therapeutics
- Highlighting 12-month stability data of liquid formulations at 2 – 80°C and improvements related to anti-PEG antibodies and response durability
- Outlining a CEPI funded rabies mRNA vaccine program
12:30 pm Showcasing Recent Progress in mRNA-Based Targeted Protein Degrader Development
Synopsis
- Presenting an update of EPDegTM bioPROTAC development
- Demonstrating proved differentiating points of bioPR
1.00 Lunch Break & Networking
Successfully Targeting Extra-Hepatic Tissues with Novel RNA Platforms Enhancing Stability, Potency & Delivery
2:00 pm Advancing mRNA/LNP Platform Technology for Innovative Vaccines & Therapeutics
Synopsis
- Showcasing a novel mRNA platform technology
- Presenting a unique LNP platform technology
- Outlining key applications of mRNA vaccine & therapeutics
2:30 pm Pioneering Next-Generation RNA–LNP Platforms & Applications
Synopsis
- Enhancing efficacy and safety in RNA delivery with novel ionizable lipid–based LNPs
- Targeting extra-hepatic delivery, including the spleen and lungs, with novel targeted LNPs
- Demonstrating effective applications in saRNA vaccines and mRNA therapeutics
3:00 pm Advancing Antibody Therapeutics Through In Vivo mRNA-LNP Delivery
Synopsis
- Presenting a novel mRNA-LNP platform optimized for in vivo expression of therapeutic antibodies, including bispecific antibodies
- Exploring therapeutic antibody potential from discovery to pre-clinical development
- Overcoming key challenges of in vivo protein expression for successful translation of mRNA-based therapeutics
3:30 pm Progressing mRNA-LNP Powered Protein Replacement Therapy for Inherited Metabolic Diseases
Synopsis
- Showcasing Innorna’s diversity-oriented lipid library
- Highlighting a preclinical efficacy study of mRNA-based protein replacement therapy for inherited metabolic diseases
- Demonstrating effective LNP delivery beyond the liver
4.00 Afternoon Break & Networking
The Next Wave: Advancing Next Generation RNA Technologies to Achieve Better Dosing & Safety in Patients
4:30 pm The Opportunities for Chinese Genetic Medicine
Synopsis
- Overview of Chinese genetic medicine development
- Current development on technology platforms and products
- AnlongBio's exploration on siRNA technologies
5:00 pm Targeting lncRNA TUG1 for Treatment of Patients with GBM by Using a Novel DDS for ASO – New Data
Synopsis
- Presenting a novel drug delivery system for antisense oligonucleotides
- Achieving success in non-clinical experiments
- Showcasing early clinical results